GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (HKSE:01349) » Definitions » Gross Profit

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Gross Profit : HK$810.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gross profit for the three months ended in Mar. 2024 was HK$148.6 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was HK$810.3 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's gross profit for the three months ended in Mar. 2024 was HK$148.6 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was HK$160.4 Mil. Therefore, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Margin % for the quarter that ended in Mar. 2024 was 92.63%.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co had a gross margin of 92.63% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 92.90%. The lowest was 88.99%. And the median was 92.02%.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,063.74 911.59 1,297.15 1,057.64 853.26

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 195.68 338.47 184.23 139.03 148.58

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit falls into.



Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=930.514 - 77.252
=853.3

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=160.389 - 11.813
=148.6

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$810.3 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=148.6 / 160.389
=92.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (HKSE:01349) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co had a gross margin of 92.63% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Business Description

Traded in Other Exchanges
Address
No. 308, Cai Lun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Headlines

No Headlines